Search

Displaying results 6131 - 6140 of 10000 in total
  1. Drug

    Amphiachyris dracunculoides pollen

    go.drugbank.com/drugs/DB10967
    Approved

    Amphiachyris dracunculoides pollen is mainly used in allergenic testing.

  2. Drug

    Iva angustifolia pollen

    go.drugbank.com/drugs/DB10968
    Approved

    Iva angustifolia pollen is mainly used in allergenic testing.

  3. Drug

    Canis lupus familiaris dander

    go.drugbank.com/drugs/DB11018
    Approved

    Canis lupus familiaris dander is used in allergenic testing.

  4. Drug

    Rosemary

    go.drugbank.com/drugs/DB14272
    Investigational

    Rosemary is a plant/plant extract used in some OTC (over-the-counter) products. It is not an approved drug.

  5. Drug

    Perazine

    go.drugbank.com/drugs/DB12710
    ApprovedWithdrawn

    Perazine has been used in trials studying the treatment of Dementia, Depression, Schizophrenia, Anxiety Disorders, and Psychosomatic Disorders, among others.

  6. Drug

    Bromperidol

    go.drugbank.com/drugs/DB12401
    ApprovedWithdrawn

    Bromperidol has been used in trials studying the treatment of Dementia, Depression, Schizophrenia, Anxiety Disorders, and Psychosomatic Disorders, among others.

  7. Drug

    Koeleria macrantha pollen

    go.drugbank.com/drugs/DB10949
    Approved

    Koeleria macrantha pollen is mainly used in allergenic testing.

  8. Drug

    Imiglucerase

    go.drugbank.com/drugs/DB00053
    ApprovedInvestigational

    Human Beta-glucocerebrosidase or Beta-D-glucosyl-N-acylsphingosine glucohydrolase E.C. 3.2.1.45. 497 residue protein with N-linked carbohydrates, MW=59.3 kD.

  9. Drug

    Bexotegrast

    go.drugbank.com/drugs/DB16515
    Investigational

    In addition, the compound is also currently in Phase 2a trials (NCT04565249) for the treatment of COVID-19 related acute respiratory distress syndrome[L31713]. … The compound was granted orphan drug designation by the US FDA in August 2018 for treatment of IPF, and Pliant Therapeutics recently raised $100 million in Series C financing to support further clinical

  10. Drug

    Azelnidipine

    go.drugbank.com/drugs/DB09230
    Investigational

    It is marketed by Daiichi-Sankyo pharmaceuticals, Inc. in Japan. … It has a gradual onset of action and produces a long-lasting decrease in blood pressure, with only a small increase in heart rate, unlike some other calcium channel blockers [L1379].